These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27014271)

  • 41. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Noorbakhsh F; Tsutsui S; Vergnolle N; Boven LA; Shariat N; Vodjgani M; Warren KG; Andrade-Gordon P; Hollenberg MD; Power C
    J Exp Med; 2006 Feb; 203(2):425-35. PubMed ID: 16476770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis.
    Constantin G; Marconi S; Rossi B; Angiari S; Calderan L; Anghileri E; Gini B; Bach SD; Martinello M; Bifari F; Galiè M; Turano E; Budui S; Sbarbati A; Krampera M; Bonetti B
    Stem Cells; 2009 Oct; 27(10):2624-35. PubMed ID: 19676124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
    Mishra MK; Wang J; Keough MB; Fan Y; Silva C; Sloka S; Hayardeny L; Brück W; Yong VW
    Ann Clin Transl Neurol; 2014 Jun; 1(6):409-22. PubMed ID: 25356411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms.
    Levin MC; Douglas JN; Meyers L; Lee S; Shin Y; Gardner LA
    Degener Neurol Neuromuscul Dis; 2014; 4():49-63. PubMed ID: 32669900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engine Failure in Axo-Myelinic Signaling: A Potential Key Player in the Pathogenesis of Multiple Sclerosis.
    Bergaglio T; Luchicchi A; Schenk GJ
    Front Cell Neurosci; 2021; 15():610295. PubMed ID: 33642995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in Intravital Non-Linear Optical Imaging of the Central Nervous System in Rodents.
    Rougon G; Brasselet S; Debarbieux F
    Brain Plast; 2016 Dec; 2(1):31-48. PubMed ID: 29765847
    [No Abstract]   [Full Text] [Related]  

  • 47. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment.
    Witherick J; Wilkins A; Scolding N; Kemp K
    Autoimmune Dis; 2010 Dec; 2011():164608. PubMed ID: 21197107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Editorial: Inflammation in the CNS: Advancing the Field Using Intravital Imaging.
    Pai S; Hickey MJ; Weninger W
    Front Immunol; 2017; 8():1155. PubMed ID: 29038653
    [No Abstract]   [Full Text] [Related]  

  • 49. Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
    Glatigny S; Wagner CA; Bettelli E
    J Immunol; 2016 May; 196(9):3542-6. PubMed ID: 27016608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
    Chastre A; Hafler DA; O'Connor KC
    N Engl J Med; 2016 Apr; 374(15):1495-6. PubMed ID: 27074083
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of interleukin-6 signaling in nervous tissue.
    Rothaug M; Becker-Pauly C; Rose-John S
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact.
    Clark KC; Josephson A; Benusa SD; Hartley RK; Baer M; Thummala S; Joslyn M; Sword BA; Elford H; Oh U; Dilsizoglu-Senol A; Lubetzki C; Davenne M; DeVries GH; Dupree JL
    Glia; 2016 Jul; 64(7):1190-209. PubMed ID: 27100937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple Sclerosis and Antibodies against KIR4.1.
    Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T
    N Engl J Med; 2016 Apr; 374(15):1496-8. PubMed ID: 27074084
    [No Abstract]   [Full Text] [Related]  

  • 54. Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies.
    Didonna A
    Curr Med Chem; 2016; 23(14):1442-59. PubMed ID: 27048376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
    Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
    Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
    Thell K; Hellinger R; Sahin E; Michenthaler P; Gold-Binder M; Haider T; Kuttke M; Liutkevičiūtė Z; Göransson U; Gründemann C; Schabbauer G; Gruber CW
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):3960-5. PubMed ID: 27035952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic Candidates for Alzheimer's Disease: Saponins.
    Zhang R; Zeng M; Zhang X; Zheng Y; Lv N; Wang L; Gan J; Li Y; Jiang X; Yang L
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.
    Zha Z; Liu S; Liu Y; Li C; Wang L
    Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 36009214
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.